A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
|ClinicalTrials.gov Identifier: NCT01302587|
Recruitment Status : Completed
First Posted : February 24, 2011
Last Update Posted : June 22, 2012
|Condition or disease||Intervention/treatment|
|Asthma Chronic Obstructive Pulmonary Disease (COPD) Emphysema Chronic Bronchitis||Drug: Albuterol|
|Study Type :||Observational|
|Actual Enrollment :||306 participants|
|Official Title:||A Prospective, Open Label, Assessment of [an Albuterol] Hydrofluoroalkane (HFA) Metered Dose Inhaler MDI Integrated Dose Counter|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||June 2011|
All participants in this study will receive an albuterol MDI inhaler.
Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
- The number of times the counter advanced but the inhaler did not actuate [ Time Frame: Days 1 through 46 ]MDI actuates but the counter display does not advance.
- The number of times the inhaler actuated but the counter did not advance. [ Time Frame: Days 1 through 46 ]Counter advances but the MDI does not actuate.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01302587
Show 25 Study Locations
|Study Director:||Clinical Project Leader||Teva Respiratory R&D|